Nadir CD4 Is Negatively Associated With Antinuclear Antibody Detection in HCV/HIV-Coinfected Patients.


Journal

Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005

Informations de publication

Date de publication:
01 04 2019
Historique:
pubmed: 21 12 2018
medline: 19 12 2019
entrez: 21 12 2018
Statut: ppublish

Résumé

Hepatitis C virus (HCV) and HIV infections are associated with higher risk of autoimmune diseases and T-cell dysfunction. We evaluate prevalence and factors associated with the presence of autoimmune antinuclear (ANA), anti-smooth muscle actin (aSMA), and anti-liver kidney microsome (aLKM1) antibodies (Ab) in HCV/HIV-coinfected patients during the post-combined antiretroviral therapy era. A cross-sectional observational study nested in the ANRS CO13 HEPAVIH cohort (NCT number: NCT03324633). We selected patients with both ANA testing and T-cell immunophenotyping determination during the cohort follow-up and collected aLKM1 and aSMA data when available. Logistic regression models were built to determine factors associated with the presence of auto-Ab. Two hundred twenty-three HCV/HIV-coinfected patients fulfilled selection criteria. Prevalence of ANA and aSMA was 43.5% and 23.2%, respectively, and both were detected in 13.3% of patients. Isolated aSMA were detected in 9.9% and aLKM1 in 2 patients. In multivariable analysis, only a low nadir CD4 T-cell count was significantly associated with ANA detection. ANA and aSMA detection remain frequent in HCV/HIV-coinfected patients during the post-combined antiretroviral therapy era, despite fair immune restoration. These results advocate for a close monitoring of ANA before immune checkpoint inhibitor therapy in these patients with greater caution for those with a low nadir CD4 T-cell count.

Sections du résumé

BACKGROUND
Hepatitis C virus (HCV) and HIV infections are associated with higher risk of autoimmune diseases and T-cell dysfunction.
SETTING
We evaluate prevalence and factors associated with the presence of autoimmune antinuclear (ANA), anti-smooth muscle actin (aSMA), and anti-liver kidney microsome (aLKM1) antibodies (Ab) in HCV/HIV-coinfected patients during the post-combined antiretroviral therapy era.
METHODS
A cross-sectional observational study nested in the ANRS CO13 HEPAVIH cohort (NCT number: NCT03324633). We selected patients with both ANA testing and T-cell immunophenotyping determination during the cohort follow-up and collected aLKM1 and aSMA data when available. Logistic regression models were built to determine factors associated with the presence of auto-Ab.
RESULTS
Two hundred twenty-three HCV/HIV-coinfected patients fulfilled selection criteria. Prevalence of ANA and aSMA was 43.5% and 23.2%, respectively, and both were detected in 13.3% of patients. Isolated aSMA were detected in 9.9% and aLKM1 in 2 patients. In multivariable analysis, only a low nadir CD4 T-cell count was significantly associated with ANA detection.
CONCLUSIONS
ANA and aSMA detection remain frequent in HCV/HIV-coinfected patients during the post-combined antiretroviral therapy era, despite fair immune restoration. These results advocate for a close monitoring of ANA before immune checkpoint inhibitor therapy in these patients with greater caution for those with a low nadir CD4 T-cell count.

Identifiants

pubmed: 30570526
doi: 10.1097/QAI.0000000000001940
doi:

Substances chimiques

ACTA2 protein, human 0
Actins 0
Antibodies, Antinuclear 0

Banques de données

ClinicalTrials.gov
['NCT03324633']

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

461-466

Auteurs

Isabelle Poizot-Martin (I)

Service d'Immuno-hématologie clinique, APHM Hôpital Sainte-Marguerite, Aix-Marseille Univ, Marseille, France.
Aix Marseille Univ, APHM, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Hôpital Sainte- Marguerite, Service d'Immuno-hématologie clinique, Marseille, France.

Eric Rosenthal (E)

Service de Médecine Interne, Hôpital l'Archet, Centre Hospitalier Universitaire de Nice, Nice, France.
Université de Nice-Sophia Antipolis, Nice, France.

Camille Gilbert (C)

Bordeaux Population Health Research Center, UMR 1219, ISPED, Inserm, Université de Bordeaux, CIC-EC 1401, Bordeaux, France.

Carla E Cano (CE)

Service d'Immuno-hématologie clinique, APHM Hôpital Sainte-Marguerite, Aix-Marseille Univ, Marseille, France.

Anne Simon (A)

Service de Médecine Interne, Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France.

Caroline Lascoux-Combe (C)

Service des Maladies Infectieuses, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris, Paris, France.

Laurent Alric (L)

Service Médecine interne-Pôle Digestif, Hôpital Purpan, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
UMR 152 IRD Université Toulouse III, Paul Sabatier, Toulouse, France.

Anne Gervais (A)

Service des Maladies Infectieuses, Hôpital Bichat-Claude Bernard, Assistance Publique des Hôpitaux de Paris, Paris, France.

Didier Neau (D)

Service des Maladies Infectieuses et Tropicales, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France.

Laure Esterle (L)

Bordeaux Population Health Research Center, UMR 1219, ISPED, Inserm, Université de Bordeaux, CIC-EC 1401, Bordeaux, France.

Dominique Salmon (D)

Unité des Maladies infectieuses et tropicales, Hôpitaux Universitaires Paris Centre, Hôpital Hôtel Dieu, Assistance Publique des Hôpitaux de Paris, Paris, France.
Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

Philippe Sogni (P)

Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Service d'Hépatologie, Hôpital Cochin, Assistance Publique des Hôpitaux de Paris, Paris, France.
Inserm U-1223-Institut Pasteur, Paris, France.

Linda Wittkop (L)

Bordeaux Population Health Research Center, UMR 1219, ISPED, Inserm, Université de Bordeaux, CIC-EC 1401, Bordeaux, France.
Service d'information médicale, Pôle de santé publique, CHU de Bordeaux, Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH